Biarylmethoxy isonipecotanilides as potent and selective inhibitors of blood coagulation factor Xa

European Journal of Pharmaceutical Sciences

Volumn 42, Issue 3, 2011, Pages 180-191

  Lopopolo, Gianfranco ^a   Fiorella, Filomena ^a   De Candia, Modesto ^a   Nicolotti, Orazio ^a   Martel, Sophie ^b   Carrupt, Pierre Alain ^b   Altomare, Cosimo ^a  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

Anticoagulant; Factor Xa inhibitor; Piperidine 4 carboxamide; Thromboembolism

Indexed keywords

1 [3 (AMINOMETHYL)PHENYL] N [3 FLUORO 2' (METHYLSULFONYL)[1,1' BIPHENYL] 4 YL] 3 (TRIFLUOROMETHYL) 1H PYRAZOLE 5 CARBOXAMIDE; 1,1' BIPHENYLMETHOXY ISONIPECOTANILIDE DERIVATIVE; 2 [[5 (4 CHLOROPHENYL)ISOXAZOL 3 YL]METHOXY]ANILINE; 5 (4 CHLOROPHENYL) 3 [(2 NITROPHENOXY)METHYL]ISOXAZOLE; AMIDINE; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; BMS 562247 1; FXV 673; ISONIPECOTAMIDE DERIVATIVE; N [2 [[5 (4 CHLOROPHENYL)ISOXAZOL 3 YL]METHOXY]PHENYL]PIPERIDINE 4 CARBOXAMIDE; N [3 [(4' CHLORO 1,1' BIPHENYL 4 YL)METHOXY]PHENYL] 1 CARBAMIMIDOYLPIPERIDINE 4 CARBOXAMIDE; N [3 [(4' CHLORO 1,1' BIPHENYL 4 YL)METHOXY]PHENYL]PIPERIDINE 4 CARBOXAMIDE; N [3 [(4' FLUORO 1,1' BIPHENYL 4 YL)METHOXY]PHENYL] 1 (1 METHYLETHYL)PIPERIDINE 4 CARBOXAMIDE; OTAMIXABAN; PIPERIDINE; RAZAXABAN; RIVAROXABAN; THROMBIN; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; CRYSTAL STRUCTURE; DRUG STRUCTURE; DRUG SYNTHESIS; MOLECULAR MODEL; PRIORITY JOURNAL; PROTHROMBIN TIME; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANILIDES; FACTOR XA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; SERINE PROTEINASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROPHOTOMETRY, INFRARED; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79251593914     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2010.11.010     Document Type: Article

References (45)

1. F. Al-Obeidi, and J.A. Ostrem Factor Xa inhibitors Expert Opin. Ther. Patents 9 1999 931 953
2. J. Ansell Factor Xa or thrombin: is factor Xa a better target? J. Thromb. Haemostasis 5 Suppl. 1 2007 60 64
3. R. Appel Tertiary phosphane/tetrachloromethane, a versatile reagent for chlorination, dehydration, and P-N linkage Angew. Chem., Int. Ed. 14 1975 801 811
4. G.M. Arepally, and T.L. Ortel Heparin-induced trombocitopenia N. Engl. J. Med. 355 2006 809 817
5. B. Bard, P.-A. Carrupt, and S. Martel Lipophilicity of basic drugs measured by hydrophilic interaction chromatography J. Med. Chem. 52 2009 3416 3419
6. M. Böhm, J. Stürzebecher, and G. Klebe Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa J. Med. Chem. 42 1999 458 477
7. 50) of an enzymatic reaction Biochem. Pharmacol. 22 1973 3099 3108
8. M. de Candia, G. Lopopolo, and C. Altomare Novel factor Xa inhibitors: a patent review Expert Opin. Ther. Patents 19 2009 1535 1580
9. M. de Candia, F. Liantonio, A. Carotti, R. De Cristofaro, and C. Altomare Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation J. Med. Chem. 52 2009 1018 1028
10. Guillot, A., 2010, Development of experimental methods to determine high lipophilicity of new chemical compounds. Ph.D. Thesis, Applications to Cyclosporin A and Bioconcentration, School of pharmaceutical sciences, University of Geneva, University of Lausanne.
11. N. Haginoya, S. Kobayashi, S. Komoriya, Y. Hirokawa, T. Furugori, and T. Nagahara Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine derivatives Bioorg. Med. Chem. Lett. 14 2004 2935 2939
12. G. Jones, P. Willett, R.C. Glen, A.R.L. Leach, and R. Taylor Development and validation of a genetic algorithm for flexible docking J. Mol. Biol. 267 1997 727 748
13. E. Krynetskiy, and P. McDonnell Building individualized medicine: prevention of adverse reactions to warfarin therapy J. Pharmacol. Exp. Ther. 322 2007 427 434
14. P.Y. Lam, C.G. Clark, R. Li, D.J. Pinto, M.J. Orwat, R.A. Galemmo, J.M. Fevig, C.A. Teleha, R.S. Alexander, A.M. Smallwood, K.A. Rossi, M.R. Wright, S.A. Bai, K. He, J.M. Luettgen, P.C. Wong, R.M. Knabb, and R.R. Wexler Structure-based design of novel guanidine/benzamidine mimics: potent and orally bioavailable Factor Xa inhibitors as novel anticoagulants J. Med. Chem. 46 2003 4405 4418
15. R.J. Leadley Coagulation factor Xa inhibition: biological background and rationale Curr. Top. Med. Chem. 1 2001 151 159
16. 2/TBAB/PEG-400 system for Suzuki-Miyaura cross-coupling reaction under ligand-free condition Synthesis 5 2006 860 864
17. W.C. Lumma Jr., K.M. Witherup, T.J. Tucker, S.F. Brady, J.T. Sisko, A.M. Naylor-Olsen, S.D. Lewis, B.J. Lucas, and J.P. Vacca Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P1 substructures: rapid structure-activity studies by solid-phase synthesis J. Med. Chem. 1998 1998 1011 1013
18. N. Mackman Triggers, targets and treatment for thrombosis Nature 451 2008 914 918
19. S. Maignan, and V. Mikol The use of 3D structural data in the design of specific factor Xa inhibitors Curr. Top. Med. Chem. 1 2001 161 174
20. S. Maignan, J.P. Guilloteau, Y.M. Choi-Sledeski, M.R. Becker, W.R. Ewing, H.W. Pauls, A.P. Spada, and V. Mikol Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: preference for a neutral group in the S1 pocket J. Med. Chem. 46 2003 685 690
21. C. McMartin, and R.S. Bohacek QXO: powerful, rapid computer algorithms for structure-based drug design J. Comput. Aided Mol. Des. 11 1997 333 344
22. J.M.A. Miguez, L.A. Adrio, A. Sousa-Pedrares, J.M. Vila, and K.K. Hii A practical and general synthesis of unsymmetrical terphenyls J. Org. Chem. 72 2007 7771 7774
23. O. Mitsunobu The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products Synthesis 1981 1 28
24. M. Murcia, A. Morreale, and A.R. Ortiz Comparative binding energy analysis considering multiple receptors: a step toward 3D-QSAR models for multiple targets J. Med. Chem. 49 2006 6241 6253
25. M. Nazaré, M. Essrich, D.W. Will, H. Matter, K. Ritter, M. Urmann, A. Bauer, H. Schreuder, A. Dudda, J. Czech, M. Lorenz, V. Laux, and V. Wehner Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral PI substituents Bioorg. Med. Chem. Lett. 14 2004 4191 4195 (Pubitemid 38916933)
26. M. Nazaré, D.W. Will, H. Matter, H. Schreuder, K. Ritter, M. Urmann, M. Essrich, A. Bauer, M. Wagner, J. Czech, M. Lorenz, V. Laux, and V. Wehner Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography J. Med. Chem. 48 2005 4511 4525
27. O. Nicolotti, T.F. Miscioscia, A. Carotti, F. Leonetti, and A. Carotti An integrated approach to ligand- and structure-based drug design: development and application to a series of serine protease inhibitors J. Chem. Inf. Model. 48 2008 1211 1226
28. O. Nicolotti, I. Giangreco, T.F. Miscioscia, and A. Carotti Improving quantitative structure-activity relationships through multiobjective optimization J. Chem. Inf. Model. 49 2009 2290 2302
29. O. Nicolotti, I. Giangreco, T.F. Miscioscia, M. Convertino, F. Leonetti, L. Pisani, and A. Carotti Screening of benzamidine-based thrombin inhibitors via a linear interaction energy in continuum electrostatics models J. Comput. Aided Mol. Des. 24 2010 117 129
30. J.W. Nissink, C. Murray, M. Hartshorn, M.L. Verdonk, J.C. Cole, and R. Taylor A new test set for validating predictions of protein-ligand interaction Proteins 49 2002 457 471
31. G. Ottaviani, S. Martel, C. Escarala, E. Nicolle, and P.-A. Carrupt The PAMPA technique as a HTS tool for partition coefficients determination in different solvent/water systems Eur. J. Pharm. Sci. 35 2008 68 75
32. D.J.P. Pinto, M.J. Orwat, S. Wang, J.M. Fevig, M.L. Quan, E. Amparo, J. Cacciola, K.A. Rossi, R.S. Alexander, A.M. Smallwood, J.M. Luettgen, L. Liang, B.J. Aungst, M.R. Wright, R.M. Knabb, P.C. Wong, R.R. Wexler, and P.Y.S. Lam Discovery of 1-[3-(aminomethyl)phenyl]-N-[3-fluoro-20-(methylsulfonyl)-[1,10- biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa J. Med. Chem. 2001 566 578
33. D.J. Pinto, M.J. Orwat, S. Koch, K.A. Rossi, R.S. Alexander, A. Smallwood, P.C. Wong, A.R. Rendina, J.M. Luettgen, R.M. Knabb, K. He, B. Xin, R.R. Wexler, and P.Y.S. Lam Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2- oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c] pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa J. Med. Chem. 50 2007 5339 5356
34. D.J.P. Pinto, J.M. Smalheer, D.L. Cheney, R.M. Knabb, and R.R. Wexler Factor Xa inhibitors: next-generation antithrombotic agents J. Med. Chem. 53 2010 6243 6274
35. M.L. Quan, P.Y. Lam, Q. Han, D.J. Pinto, M.Y. He, R. Li, C.D. Ellis, C.G. Clark, C.A. Teleha, J.H. Sun, R.S. Alexander, S. Bai, J.M. Luettgen, R.M. Knabb, P.C. Wong, and R.R. Wexler Discovery of 1-(3′-aminobenzisoxazol- 5′-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2′-dimethylaminomethyl) imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor J. Med. Chem. 48 2005 1729 1744
36. M. Remko Molecular structure, lipophilicity, solubility, absorption, and polar surface area of novel anticoagulant agents J. Mol. Struct. Theochem. 916 2009 76 85
37. S. Roehrig, A. Straub, J. Pohlmann, T. Lampe, J. Pernerstorfer, K.H. Schlemmer, P. Reinemer, and E. Perzborn Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin- 5-yl}methyl)thiphene-2-carboxamide (BAY59-7939): an oral, direct factor Xa inhibitor J. Med. Chem. 48 2005 5900 5908
38. M. Roses, and E. Bosch Influence of mobile phase acid-base equilibria on the chromatographic behavior of protolytic compounds J. Chromatogr. A 982 2002 1 30
39. L.M. Salonen, C. Bucher, D.W. Banner, W. Haap, J.-L. Mary, J. Benz, O. Kuster, P. Seiler, W.B. Schweizer, and F. Diederich Cation-π interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions Angew. Chem., Int. Ed. 48 2009 811 814
40. USEPA Estimation Program Interfaces Suites (EPI Suite). Version 3.2 2007 US Environmental Protection Agency Washington, DC http://www.epa.gov/opptintr/ exposure/docs/episuite.htm
41. Van Duzer, J.H., Roland, D.M., 1994. Indolyl substituted hydroxylamine derivatives. U.S. Pat. No. 5,350,761.
42. M.L. Verdonk, J.C. Cole, M.J. Hartshorn, C.W. Murray, and R.D. Taylor Improved protein-ligand docking using GOLD Proteins 52 2003 609 623
43. J.I. Weitz, and L.A. Linkins Beyond heparin and warfarin: the new generation of anticoagulants Expert Opin. Invest. Drugs 16 2007 271 282
44. F. Wohnsland, and B. Faller High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes J. Med. Chem. 44 2001 923 930
45. P.C. Wong, E.J. Crain, C.A. Watson, and B. Xin Favorable therapeutic index of the direct factor Xa inhibitors, apixaban and rivaroxaban, compared with the thrombin inhibitor dabigatran in rabbits J. Thromb. Haemostasis 7 2009 1313 1320